TruthArchive.ai - Related Video Feed

Video Saved From X

reSee.it Video Transcript AI Summary

I found something interesting for Elon and the Doge team regarding Medicare. In 2022, Medicare filled 85,000 prescriptions for Perfinidone at $8,000 each, totaling $680 million. At my cost-plus pharmacy, the same prescription is only $200. Filling all 85,000 prescriptions with me would only cost $17 million. Medicare is overpaying by $663 million annually because Pharmacy Benefits Managers (PBMs) get a percentage of the cost, incentivizing them to inflate prices. The easy solution is to cancel the PBM contracts and use actual costs. If you want to check if PBMs have been raising the cost of your medications, go to forestparkpharmacy.com and check our price to see how much you could save.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker's administration will implement "most favored nations" drug pricing, ensuring Americans pay the lowest price for drugs compared to other developed countries. Some prescription drug prices will be reduced almost immediately by 50% to 90%. Big Pharma must voluntarily comply or the federal government will ensure equal pricing. To accelerate price reductions, the administration will cut out the middlemen to facilitate direct drug sales to American citizens at the most favored nation price. The speaker believes the middlemen are worse than drug companies because they don't make a product but make a fortune.

Video Saved From X

reSee.it Video Transcript AI Summary

One breast cancer drug costs over $16,000 per bottle in America. The same drug, from the same factory and company, costs one sixth the price in Australia. In Sweden, the identical product costs one tenth the American price.

Video Saved From X

reSee.it Video Transcript AI Summary

A businessman told the speaker that the same fat shot drug cost him $88 in London, but $1,300 in New York. He was stunned that the identical pill, made in the same plant by the same company, had such different prices. The speaker discussed this with drug company representatives. They argued for about half an hour, but ultimately the representative admitted there was no justification for the price difference.

Video Saved From X

reSee.it Video Transcript AI Summary

The speaker claims the United States spends $1,126 per capita on drugs, while Britain spends about $240, approximately one-fifth of the U.S. figure, a trend seen across Europe. The speaker says drug companies claim America must pay for pharmaceutical innovation. President Trump is quoted as saying European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. should no longer subsidize it. The speaker concludes that if Europeans raised drug prices by 20%, the resulting $10 trillion could be spent on innovation, improving global health.

Video Saved From X

reSee.it Video Transcript AI Summary

Brenzavvy, a drug similar to Jardiance or Farxiga, is not covered by insurance, prescribed by doctors, or carried by wholesalers because it is too cheap. Brenzavvy costs $60 at the speaker's pharmacy. Pharmacy benefits managers (PBMs) deny coverage because Brenzavvy's low price prevents rebates. Farxiga and Jardiance cost insurance payers $1,000 upfront with a 40% rebate. An HHS report stated PBMs get 23% on average for brand meds. After rebates, Farxiga and Jardiance still cost $600, with PBMs earning $138. With 8,000,000 prescriptions a year, PBMs make $1,100,000,000 off those two drugs. The speaker claims PBMs keep Brenzavvy off their lists to avoid losing a billion dollars annually. The speaker believes affordable healthcare is impossible with PBMs involved. The speaker encourages listeners to use forestpark.pharmacy to save money and to inform their bosses about potential savings.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the current system was fair, even though the reasons why were not widely understood.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies claimed research and development costs had to be borne by America alone, which effectively meant American patients were subsidizing socialist healthcare systems in places like Germany and the European Union. The speaker believes the European Union is nastier than China and has treated the U.S. unfairly. However, the speaker asserts that the U.S. now holds all the cards and expects the European Union to concede.

Video Saved From X

reSee.it Video Transcript AI Summary

The U.S. spends $1,126 per capita on drugs, while Britain spends about $240, roughly one-fifth of the U.S. amount, a trend seen across Europe. Drug companies claim America must pay for innovation. President Trump argues that European partners need to increase their drug payments to cover their share of innovation, asserting the U.S. will no longer subsidize them. If Europeans raise drug prices by 20%, $10 trillion could be spent on innovation, improving global health through better products.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies generate over two-thirds of their profits in the United States, despite the U.S. accounting for only 4% of the world's population. The speaker expresses respect for pharmaceutical companies and their leadership. They believe these companies successfully convinced people for many years that the existing system was fair, even though the reasons why were not well understood. The speaker claims to have figured out the reasons behind this.

Video Saved From X

reSee.it Video Transcript AI Summary

Pharmaceutical companies claimed high R&D costs had to be borne solely by America, effectively subsidizing socialist healthcare systems in countries like Germany and the European Union. The speaker believes the European Union is "nastier than China" and has treated the U.S. unfairly, but predicts they will concede because the U.S. "has all the cards."

Video Saved From X

reSee.it Video Transcript AI Summary

Politicians have long promised to eliminate the discrepancy between drug prices in the U.S. and Europe. This was a key issue for Bernie Sanders, but previous leaders haven't acted on it. Politicians make these promises knowing they likely won't have to fulfill them. The reason is that Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every congressman, senator, and Supreme Court member.

Video Saved From X

reSee.it Video Transcript AI Summary

We're paying too much for drugs compared to other countries, and existing laws make it hard to lower costs. The middlemen in the drug industry are profiting significantly without adding value. We're going to eliminate these middlemen to reduce drug prices to unprecedented levels. This topic dominated our discussions with executives and others involved.

Video Saved From X

reSee.it Video Transcript AI Summary

Medicare overspent on dimethyl fumarate in 2022, paying $590 million for a drug I offer at $65 per prescription. This discrepancy highlights how Pharmacy Benefits Managers (PBMs) inflate drug costs to increase their profits. Medicare's PBM charged them $3,800 per prescription when the real price is only $65. This PBM price gouging cost Medicare $580 million on just this one drug. The solution is simple: eliminate PBM contracts to save money. Also, your insurance likely uses a PBM, overcharging you too. Check if you're overpaying for your medications at fourthparkpharmacy.com to use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary

One breast cancer drug costs Americans over $16,000 per bottle. The same drug, from the same factory, manufactured by the same company, costs one-sixth the price in Australia. In Sweden, the identical product costs one-tenth the price.

Video Saved From X

reSee.it Video Transcript AI Summary

Speaker 1 reveals that Bear Corporation knowingly sold medication infected with the AIDS virus. They pulled the product from the US market and dumped it in France, Europe, Asia, and Latin America to make a profit. Shockingly, no corporate executives have been indicted or investigated by the US Justice Department. The FDA allowed this to happen, resulting in the deaths of thousands of innocent hemophiliacs and their family members. The government is turning a blind eye to the situation.

Video Saved From X

reSee.it Video Transcript AI Summary

Speaker 0 expresses frustration over a price discrepancy in a prescription transaction. The core facts cited are: a medication that costs $4 to dispense, when billed to the insurance, results in the patient being charged $97.06. Speaker 0 repeats the puzzling situation: “We have a claim for a prescription that costs less than $4. The insurance wants to charge the patient $97.” The concern is the patient’s likely reaction: they will be yelled at and blame CVS for the high price set by their insurance, even though the dispensing cost is described as less than $4. Speaker 0 highlights the misalignment between the pharmacy’s dispensing cost and the amount the patient is asked to pay after insurance processing, indicating a breakdown in the expected pricing flow from the pharmacy to insurance to patient. The dialogue underscores the emotional and reputational pressure on the pharmacy staff when patients perceive the price as excessive, regardless of where the markup originates. The closing sentiment, “Love you CVS,” signals a mixture of familiarity and exasperation with the CVS system or process involved in this pricing scenario, though the exact sentiment toward CVS is not elaborated beyond that line.

Video Saved From X

reSee.it Video Transcript AI Summary

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker highlights the significant price difference, noting one person paid a small amount for the same shot in the UK. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world, according to the speaker, who questions the reason for this disparity.

Video Saved From X

reSee.it Video Transcript AI Summary

I've identified wasteful spending in Medicare, specifically with generic Cialis, or Tadalafil. In 2022, Medicare spent $237 million on this drug, averaging $481 per prescription across 492,000 prescriptions. However, at my pharmacy, the same prescription costs only $14 without insurance. That means it would only cost $7 million to cover the entire country at my pharmacy's pricing. The overcharge of $230 million for just this one drug is due to pharmacy benefits managers (PBMs). PBMs manage all pharmacy-related aspects for Medicare, deciding coverage, copays, government costs, and pharmacy payments. They've essentially decided on a 3000% markup. It's time to fire the PBMs and bring prices back to reality. To check the markups on your prescriptions, visit forestparkpharmacy.com and use our price checker.

Video Saved From X

reSee.it Video Transcript AI Summary

Politicians have long promised to address the discrepancy between drug prices in the U.S. and Europe. This issue was central to Bernie Sanders' presidential campaigns. However, these promises were never fulfilled because Congress is heavily influenced by the pharmaceutical industry. There is at least one pharmaceutical lobbyist for every member of Congress, the Senate, and the Supreme Court.

Video Saved From X

reSee.it Video Transcript AI Summary

A common asthma drug costs almost $500 in America, but less than $40 in The United Kingdom. The speaker stated that an individual in the UK paid a small amount for their shot, contrasting sharply with the $500 cost in the US. The weight loss drug Ozempic costs 10 times more in The United States than in the rest of the developed world. The speaker questions the reason for this disparity.

Video Saved From X

reSee.it Video Transcript AI Summary

Americans pay significantly more for prescription drugs than other countries, sometimes up to 10 times more. Pharmaceutical companies generate two-thirds of their profits in the U.S., effectively making Americans subsidize healthcare in other countries. The administration is introducing a "most favored nation" pricing model, ensuring the U.S. pays the lowest price available globally for drugs. For example, a breast cancer drug costing over $16,000 in the U.S. is a fraction of that price in Australia and Sweden. Similarly, an asthma drug costs almost $500 in the U.S. but less than $40 in the UK. The plan involves directing investigations into foreign nations that block drug products unless they accept low prices, and the U.S. will defend drug companies from unfair pricing demands. The administration aims to cut out middlemen and facilitate direct drug sales at the most favored nation price. If companies don't comply, the U.S. will use its trade powers and open the market to safe, legal drug imports.

TED

What if all US health care costs were transparent? | Jeanne Pinder

Guests: Jeanne Pinder

reSee.it Podcast Summary

Jeanne Pinder discusses her family's experience with exorbitant healthcare bills, revealing significant price variations for procedures. She founded a company to promote price transparency in healthcare, enabling patients to share costs and save money. Pinder emphasizes the need for public pricing to alleviate financial burdens in the healthcare system.

American Alchemy

Martin Shkreli on Life in Prison, Pharma, UFO’s

Guests: Martin Shkreli

reSee.it Podcast Summary

Jesse Michels sits down with Martin Shkreli for a long, no-holds-barred talk about gain-of-function debates, reality, and intelligence. Shkreli argues the mind is a classical computer, though a fairly insignificant one, and he weighs whether we’ve passed the Turing test. He frames his public persona as a lens on a larger system, recalling the Daraprim episode—the price jumped from 13.50 to over 700—as a case study in how pricing reflects broader healthcare and regulatory structures, not just production costs. He notes that profiteering in medicine was legal, which he calls the true scandal, and he shares a fascination with Alan Turing, Enigma, and early computing, including owning an Enigma machine. Turning to AI and reality, the conversation probes whether the mind is a computer and whether we’ve already passed the Turing test. Shkreli says yes, the mind is a classical computer, and he describes AI progress as a humbling, accelerating trend that one cannot stop. He entertains simulation and mind-over-matter ideas, referencing Turing’s poems and musings, parapsychology, and the random-event generator concept. He envisions a future where AI–perhaps with instantiated bodies–gains rights and interacts with humans, while noting that technologies like GPT-3 and Dolly are making progress that reduces human centrality and challenges human self‑image. Revisiting the drug industry, Shkreli details the Daraprim episode as emblematic of a system that enables dramatic price shifts. He argues doctors don’t always choose the cheapest option because of habit, information gaps, or market dynamics, citing Bactrim as a cheaper alternative and AbbVie’s Norvir as another price example. He points to the DESI-era grandfathering of old medicines and contends that the broader problem isn’t just the price of one drug but the incentives that reward more treatments over cures. He acknowledges some value in pharma outreach and education, while insisting the overall system misaligns access, innovation, and affordability. Beyond medicine, the interview traces a software startup vision: distributed chemistry computation using AlphaFold-enabled docking and crypto incentives to lower barriers to high-throughput screening. He cites SETI@home and Folding@home as precedents and contrasts distributed ideas with DeepMind’s centralized breakthroughs. The dialogue drifts to Satoshi, blockchain, and the promise of real-world utility from encryption and crypto in science. Personal life topics appear—dating spreadsheets, polyamory, and reflections on love and family—while the thread remains that future science will demand balancing audacious ambitions with practical ethics and human needs. He also discusses his media persona and the public's reaction to his actions.

The Joe Rogan Experience

Joe Rogan Experience #1756 - John Abramson

Guests: John Abramson

reSee.it Podcast Summary

Joe Rogan and John Abramson discuss the impact of pharmaceutical companies on American healthcare, focusing on the themes presented in Abramson's book, "Sickening: How Big Pharma Broke American Health Care and How We Can Repair It." They highlight that the U.S. and New Zealand are the only countries allowing direct pharmaceutical advertising, with New Zealand having stricter oversight. Abramson explains that drug advertising in the U.S. is protected under the First Amendment, making regulation difficult. He criticizes the misleading nature of drug ads, which often omit crucial information about efficacy and side effects. The conversation shifts to the influence of pharmaceutical companies on medical practices and the healthcare system. Abramson emphasizes that the primary goal of drug companies is profit, often at the expense of patient health. He shares insights from his litigation experience, revealing how drug companies manipulate data and marketing to maximize profits, including the case of Vioxx, which caused thousands of deaths due to undisclosed risks. Rogan and Abramson discuss the lack of accountability for pharmaceutical companies, noting that fines for wrongdoing are often seen as a cost of doing business rather than a deterrent. They express concern over the rising costs of medications and the lack of government oversight in drug pricing, which leads to a healthcare system that prioritizes profit over patient care. Abramson argues that the healthcare system must be reformed to focus on preventive care and lifestyle changes, which account for 80% of health outcomes. He advocates for transparency in clinical trial data and the need for healthcare professionals to be free from pharmaceutical influence. The discussion concludes with a call for collective action to address these issues, emphasizing the importance of informed consumer choices and the need for systemic change in healthcare.